Dyne Therapeutics Analyst Price Targets

Dyne Therapeutics Inc

DYNNASDAQ

Trade with Public

$16.22

0.996.5%

Dern. MÀJ: Oct 20, 12:07 PM

$15.29

0.060.39%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Dyne Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dyne Therapeutics (DYN).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

15Buy

1Hold

1Sell

Consensus RatingOutperform# Analysts18Avg. Consensus PT$38Upside to Avg. PT+134.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Sep 30, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$50→$32
Sep 29, 2026	Piper Sandler	Edward Tenthoff	Maintained	Overweight	$47
Sep 9, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$45→$36
Sep 9, 2026	JP Morgan	Tessa Romero	Downgrade	Neutral→Underweight	$17→$10
Sep 9, 2026	RBC Capital	Luca Issi	PT Cut	Outperform	$35→$30
Sep 9, 2026	Baird	Brian Skorney	PT Cut	Outperform	$30→$26
Jul 31, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$47→$45
Jul 30, 2026	RBC Capital	Luca Issi	PT Raise	Outperform	$30→$35
Jul 23, 2026	Cantor Fitzgerald	Eric Schmidt	Initiate	Overweight	—
Jun 26, 2026	TD Cowen	Joseph Thome	Initiate	Buy	—
May 15, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$34→$33
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$23→$24
Mar 9, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	Morgan Stanley	Michael Ulz	PT Cut	Overweight	$50→$47
Mar 3, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$38
Mar 3, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$60→$50
Jan 20, 2026	JP Morgan	Tessa Romero	PT Cut	Neutral	$17→$16
Dec 15, 2025	Evercore ISI Group	Gavin Clark-Gartner	PT Cut	Outperform	$38→$36
Dec 11, 2025	Stifel	Paul Matteis	PT Raise	Buy	$36→$39

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

HC Wainwright & Co. analyst Ananda Ghosh maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and lowers the price target from $50 to $32.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $45 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

Baird analyst Brian Skorney maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $30 to $26.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.

Benzinga Newsdesk

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

People Also Watch

People Also Watch

Dyne Therapeutics Inc

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PROPiper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PROBaird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Dyne Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PROPiper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PROBaird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PROMorgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

PRO
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

PRO
Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30

PRO
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26

PRO
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45